Recombinant DNase in cystic fibrosis: A protocol for targeted introduction through n-of-1 trials

European Respiratory Journal

Volumn 13, Issue 1, 1999, Pages 53-58

  Bollert F G E ^a   Paton, J Y ^b   Marshall, T G ^c   Calvert, J ^a   Greening, A P ^a   Innes, J A ^a,d  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^c ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^d NHS LOTHIAN   (United Kingdom)

Author keywords

Cystic fibrosis; DNase; N of 1 trials

Indexed keywords

DEOXYRIBONUCLEASE; PLACEBO; RECOMBINANT ENZYME;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG TARGETING; EXERCISE TEST; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; OXIMETRY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; SPUTUM; VISCOSITY;

EID: 0345320389     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.99.13110399     Document Type: Article

References (18)

1. Penketh ARL, Wise A, Mearns MB, Hodson ME, Batten JC. Cystic fibrosis in adolescents and adults. Thorax 1987; 42: 526-532.
2. Fitzsimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993; 122: 1-9.
3. Dodge JA, Morison S, Lewis PA, et al. Cystic fibrosis in the United Kingdom, 1968-1988: incidence, population and survival. Pediatr Perinatal Epidemiol 1993; 7: 157-166.
4. Chernick WS, Barbero GJ. Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis. Pediatrics 1959; 24: 739-745.
5. Potter J, Matthews LW, Lemm J, Spector JS. Composition of pulmonary secretions from patients with and without cystic fibrosis. Am J Dis Child 1960; 100: 493-495.
6. Lethem MI, James SL, Marriott C. The role of mucous glycoproteins in the rheologic properties of cystic fibrosis sputum. Am Rev Respir Dis 1990; 142: 1053-1058.
7. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87: 9188-9192.
8. Ramsey BW, Astley SJ, Aitken ML, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993; 148: 145-151.
9. Ranasinha C, Assoufi B, Christiansen D. et al. Efficacy and safety of short-term administration of aerolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet 1993; 342: 199-202.
10. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331: 637-642.
11. Shah PL, Scott SF, Geddes DM, Hodson ME. Two years experience with recombinant human DNase I in the treatment of pulmonary disease in cystic fibrosis. Respir Med 1995;89: 499-502.
12. Guyatt G, Sackett D, Taylor W, Chong J, Roberts R, Pugsley S. Determining optimal therapy: randomized trials in individual patients. N Engl J Med 1986; 314: 889-892.
13. Davies J, Trindade M-T, Wallis C, Rosenthal M, Crawford O, Bush A. Retrospective review of the effects of DNase in children with cystic fibrosis. Pediatr Pulmonol 1997; 23: 243-248.
14. Robson M, Abbott J, Webb K, Dodd M, Walsworth-Bell J. A cost description of an adult CF unit and cost analyses of different categories of patients. Thorax 1992; 47: 684-689.
15. Wildhagen MF, Verheij JBGM, Hilderink HBM, et al. Cost of care of patients with cystic fibrosis in The Netherlands in 1990-1. Thorax 1996; 51: 298-301.
16. Oster G, Huse DM, Lacey MJ, Regan MM, Fuchs HJ. Effects of recombinant human DNase therapy on health-care use and costs in patients with cystic fibrosis. Ann Pharmacotherapy 1995; 29: 459-464.
17. Larson EB, Ellsworth AJ, Oas J. Randomized clinical trials in single patients during a 2-year period. JAMA 1993; 270: 2708-2712.
18. Guyatt GH, Keller JL, Jaeschke R, Rosenbloom D, Adachi JD, Newhouse MT. The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience. Ann Intern Med 1990; 112: 293-299.